Clinical Trial Update: Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver Metastases [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating apatinib combined with SHR-1210 as second-line therapy in solid tumors with liver metastases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• Apatinib (apatinib)
• SHR-1210 (camrelizumab)

Snippet

Sponsor: Beijing Hospital | Conditions: Solid Tumor | Phase 2 | Status: UNKNOWN